Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Bluejay Diagnostics (BJDX) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting [Yahoo! Finance]
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics [Yahoo! Finance]